The role of DNA-profiling in predicting anticonvulsant-induced QT prolongation diseases based on pharmacogenetic aspects-Reference-Cited by-同舟云学术

The role of DNA-profiling in predicting anticonvulsant-induced QT prolongation diseases based on pharmacogenetic aspects

Published:2023-02-27 Issue:1 Volume: Page:37-52
ISSN:2588-0527
Container-title:Pharmacogenetics and Pharmacogenomics
language:
Short-container-title:Fgen_Fgenom

Author:

Zhuravlev N. M.¹^ORCID,Shnayder N. A.²^ORCID,Nasyrova R. F.¹^ORCID

Affiliation:

1. Federal State Budgetary Institution V. M. Bekhterev National Research Medical Center for Psychiatry and Neurology of the Russian Federation Ministry of Health

2. Federal State Budgetary Institution V. M. Bekhterev National Research Medical Center for Psychiatry and Neurology of the Russian Federation Ministry of Health; Federal State Budgetary Educational Institution of Higher Education “Prof. V. F. Voino-Yasenetsky Krasnoyarsk State Medical University” of the Ministry of Healthcare of the Russian Federation

Abstract

Anticonvulsants or antiepileptic drugs (AEDs) are widely used for various neurological and psychiatric diseases and are often prescribed for a long period. In this regard, the issue of their safety profile is acute, including risk assessment for the development of life-threatening conditions and adverse drug reactions (ADRs). From the point of view of personalized medicine, it is important to develop an interdisciplinary approach to the development of a new strategy for a personalized approach to predicting AED-induced prolongation of the QT interval as one of the most unfavorable prognostic cardiac ADRs (including sudden death syndrome — SDS). We searched the databases of full-text publications for the period from 2012 to 2022 for keywords and their combinations. We have discovered and systematized monogenic and multifactorial forms of long QT syndrome (LQTS) and candidate genes that slow down AEDs metabolism in the liver. Identification of risk alleles of single nucleotide variants (SNV) of candidate genes predisposing to the development of AED-induced LQTS and SDS will allow adjusting the choice and dosage of these drugs and preventing the development of the ADR, which will improve the quality of life and help prevent SDS in patients with mental and neurological disorders

Publisher

Publishing House OKI

Subject

General Medicine

Reference66 articles.

1. Карлов В. А. Эпилепсия у детей и взрослых мужчин и женщин. М.: БИНОМ-Пресс, 2019. 896 с. [Karlov VA. Epilepsiya u detej i vzroslyh muzhchin i zhenshchin. Moscow: BINOM-Press, 2019. (In Russ).].

2. Шнайдер Н. А., Петрова М. М., Петров К. В., Насырова Р. Ф. Фармакологические предикторы нарушения сердечного ритма и проводимости при юношеской миоклонической эпилепсии. Эпилепсия и пароксизмальные состояния. 2021;13(2):168–79. [Shnayder NA, Petrova MM, Petrov KV, Nasyrova RF. Pharmacological predictors of heart rate and conductivity disorders in juvenile myoclonic epilepsy. Epilepsiya i paroksizmalʹnye sostoyania = Epilepsy and Paroxysmal Conditions. 2021;13(2):168–179. (In Russ).]. DOI: 10.17749/2077-8333/epi.par.con.2021.051

3. Бородулина И. В., Рачин А. П. Полинейропатии в практике врача: особенности патогенеза, клиники и современные подходы к лечению болевых и безболевых форм. РМЖ. 2016;25:1705–1710. [Borodulina IV, Rachin AP. Polyneuropathies: pathogenesis, clinical manifestations, and current treatment approaches to painful and painless conditions. RMJ. 2016;25:1705–1710. (In Russ).].

4. Auerbach DS, Biton Y, Polonsky B, McNitt S, Gross RA, Dirksen RT, Moss AJ. Risk of cardiac events in Long QT syndrome patients when taking antiseizure medications. Transl Res. 2018 Jan;191:81–92.e7. DOI: 10.1016/j.trsl.2017.10.002

5. Talaeı A, Farıdhosseını F, Kazemı H, Fayyazı Bordbar MR, Rezaeı Ardanı A. Topiramatın Şizofreni ve İki Uçlu Duygudurum I Bozukluğu Olan Hastalarda İlaca Bağlı Kilo Alımına Etkileri: Doz Ayarlarının Seçkisiz Klinik Çalışması. [Effect of Topiramate on Drug Associated Weight Gain of Patients with Schizophrenia and Bipolar I Disorders: A Dose Ranging Randomized Trial]. Turk Psikiyatri Derg. 2016 Summer;27(2):0. Turkish. PMID: 27370059.